Investigation of the effectiveness of whole wheat bread intake for 12 weeks against metabolic syndrome index: Effects on visceral fat area, fasting blood glucose and serum lipids.
- Conditions
- Healthy subjects ( BMI >= 23.0 kg/m2)
- Registration Number
- JPRN-UMIN000018673
- Lead Sponsor
- CPCC Company Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
(1) Subjects who have continuous intake of Divaricate Saposhnikovia Miraculous Powder. (2) Subjects who take drugs to treat dyslipidemia. (3) Subjects who experienced body weight changes >= 10% within a year before the start date of this study. (4) Fasting blood glucose >=126 mg/dl or HbA1c (NGSP) >=6.5% or diabetic patient. (5) Subjects who have previous and/or current medical history of serious disease (e.g., heart, liver, kidney, digestive organ). (6) Subjects who have history of surgery in gastrointestinal tract. (7) Subjects who have history of malignant diseases. (8) Females who are pregnant or lactating, and who could become pregnant or lactating during test period. (9) Subjects who have excessive alcohol intake. (10) Subjects who have extremely irregular dining habits, and who have midnight work or irregular shift work. (11) Subjects who have continuous intake of dietary fiber supplement or whole grain. (12) Subjects who have serious infectious diseases. (13) Subjects who have previous medical history of drug and/or food allergy. (14) Subjects who are participating in other clinical tests. Subjects who participated within 4-weeks prior to the current study and/or who plan to participate in other clinical tests. (15) Subjects who donated over 200mL blood and/or blood components within the last one month. (16) Males who donated over 400mL blood within the last three month. (17) Females who donated over 400mL blood within the last four month. (18) Males who will be collected over 1200 mL of blood when the planned sampling volume in this study is added to the volume collected within the last 12 months. (19) Females who will be collected over 800 mL of blood when the planned sampling volume in this study is added to the volume collected within the last 12 months. (20) Subjects who are not eligible for this study for some medical reasons.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method metabolic syndrome index (visceral fat area, serum lipids) It will be measured at week 0, 6, and 12.
- Secondary Outcome Measures
Name Time Method Blood HbA1c, serum insulin, leptin, adiponectin levels, fasting blood glucose, blood pressure
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.